Cymabay Therapeutics Inc CBAY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:47 PM EST
8.60quote price arrow up+0.07 (+0.82%)
Volume
9,444
Close
8.53quote price arrow down-0.11 (-1.27%)
Volume
1,261,241
52 week range
1.67 - 8.74
Loading...
  • Open8.69
  • Day High8.71
  • Day Low8.18
  • Prev Close8.64
  • 52 Week High8.74
  • 52 Week High Date02/01/23
  • 52 Week Low1.67
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap722.329M
  • Shares Out84.68M
  • 10 Day Average Volume2.14M
  • Dividend-
  • Dividend Yield-
  • Beta0.25
  • YTD % Change36.04

KEY STATS

  • Open8.69
  • Day High8.71
  • Day Low8.18
  • Prev Close8.64
  • 52 Week High8.74
  • 52 Week High Date02/01/23
  • 52 Week Low1.67
  • 52 Week Low Date05/11/22
  • Market Cap722.329M
  • Shares Out84.68M
  • 10 Day Average Volume2.14M
  • Dividend-
  • Dividend Yield-
  • Beta0.25
  • YTD % Change36.04

RATIOS/PROFITABILITY

  • EPS (TTM)-1.25
  • P/E (TTM)-6.84
  • Fwd P/E (NTM)-7.81
  • EBITDA (TTM)-93.445M
  • ROE (TTM)-143.87%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,116.61%
  • Debt To Equity (MRQ)143.16%

EVENTS

  • Earnings Date03/15/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cymabay Therapeutics Inc

 

Profile

MORE
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and...
Robert Wills Ph.D.
Independent Chairman of the Board
Sujal Shah
President, Chief Executive Officer, Director
Daniel Menold
Vice President - Finance
Address
SUITE 130, 7999 GATEWAY BLVD
Newark, CA
94560
United States

Top Peers

SYMBOLLASTCHG%CHG
VKTX
Viking Therapeutics Inc
9.19+0.39+4.43%
ALT
Altimmune Inc
15.04+1.26+9.14%
EWTX
Edgewise Therapeutics Inc
10.80+0.50+4.85%
ALLK
Allakos Inc
7.57+0.17+2.30%
FDMT
4D Molecular Therapeutics Inc
23.05+1.57+7.31%